The EDSS 2 years post-IFN-β treatment (EDSSp) (3.10±0.55, mean ± SD) for the MS NSCL patients with a poor response was significantly higher than that at baseline (1.60±0.55, P = 0.009). The gene discussed is IFNB1; the disease is myeloid sarcoma.